Advertisement
Advertisement

CTNM

CTNM logo

Contineum Therapeutics, Inc. Class A Common Stock

4.60
USD
+0.22
+4.93%
Apr 17, 15:59 UTC -4
Closed
exchange

After-Market

4.60

0.00
+0.09%

Contineum Therapeutics, Inc. Class A Common Stock Profile

About

Contineum Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies which target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications with high unmet need. The company's product pipeline includes PIPE-791 and PIPE-307. Contineum Therapeutics Inc. is based in SAN DIEGO.

Info & Links

CEO

Carmine Stengone

Headquarters

3565 GENERAL ATOMICS COURT, SUITE 200
SAN DIEGO, CA 92121, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.contineum-tx.com

Auditor

Ernst & Young LLP

Share holders

--

Employees

41

Contineum Therapeutics, Inc. Class A Common Stock Statistics

Valuation Measures

Market Capitalization2

119.01M

Enterprise Value

98.52M

Enterprise Value/EBITDA(ttm)

-1.95

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.97

Price to Cash(ytd)

6.35

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-49.92%

Return on Invested Capital(ttm)

-5.25%

Return on Assets(ttm)

-20.52%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-50.64M

Net Income Available to Common(ttm)

-42.26M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

--

52-Week Change

-70.31%

S&P 500 52-Week Change

5.43%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

25.87M

Dividend Yield

0.00%

Float4

0.00

% Held by Insiders

--

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

204.76M

Total Cash Per Share(mrq)

7.91

Total Debt(mrq)

1.45M

Total Debt/Equity(mrq)

0.73%

Current Ratio(mrq)

20.69%

Quick Ratio(mrq)

37.06%

Book Value Per Share(mrq)

10.36

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.70

Free Cash Flow(ytd)

-33.34M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement